Chemours exec buys 1,934 CC shares at $15.51
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemours Co executive Michael Robert Foley, President of Titanium Technologies, purchased 1,934.2313 shares of common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.51 per share, with individual trade prices ranging from $15.51 to $15.54.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F2 | 1,934.2313 | $15.51 | $30K |
Footnotes (2)
- F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $15.51 to $15.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2. Includes directly owned shares, restricted stock units and dividend equivalent units.
Key Figures
Key Terms
weighted average price financial
restricted stock units financial
dividend equivalent units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Chemours (CC) report for Michael Robert Foley?
Was the Chemours (CC) insider trade by Michael Robert Foley a buy or a sell?
Did Chemours (CC) indicate this insider trade was under a Rule 10b5-1 plan?
What additional holdings are referenced for Michael Robert Foley in the Chemours (CC) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.